News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vyteris, Inc. to Present at Vyteris, Inc. Annual Global Investment Conference


9/7/2010 10:37:42 AM

FAIR LAWN, NJ--(Marketwire - September 07, 2010) - Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system and a leader in active transdermal drug delivery technology, today announced that President and Chief Executive Officer Haro Hartounian, Ph.D. will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 13 at 9:35 a.m. EDT at the New York Palace Hotel in New York City.

Dr. Hartounian will provide an overview of the Company and its proprietary smart patch technology, as well as an update on the Company's strategic direction. A live webcast of the presentation will be available at http://www.wsw.com/webcast/rrshq18/vytr.ob/, and will subsequently be posted to http://investor.vyteris.com/events.cfm.

More than 550 public and private companies from around the world are expected to present to an audience of over 3,500 attendees. In addition to Healthcare, the conference will also feature tracks dedicated to China, Metals & Mining, Energy, Technology, Cleantech, and REITs.

About Vyteris, Inc.
Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where the company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit us at www.vyteris.com.

Vyteris Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.


Contacts:
Joseph Himy
Chief Financial Officer
Vyteris, Inc.
Tel: (201) 703-2299


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES